© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Sunshine Biopharma, Inc. (SBFM) stock declined over -11.79%, trading at $1.24 on NASDAQ, down from the previous close of $1.40. The stock opened at $1.50, fluctuating between $1.18 and $1.50 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 06, 2026 | 1.36 | 1.47 | 1.32 | 1.40 | 253.13K |
| Aug 05, 2026 | 1.33 | 1.39 | 1.21 | 1.33 | 253.91K |
| Aug 04, 2026 | 1.22 | 1.52 | 1.16 | 1.31 | 2.39M |
| Aug 03, 2026 | 1.17 | 1.21 | 1.12 | 1.17 | 77.71K |
| Jul 31, 2026 | 1.24 | 1.24 | 1.15 | 1.17 | 79.15K |
| Jul 30, 2026 | 1.33 | 1.34 | 1.10 | 1.23 | 1.23M |
| Jul 29, 2026 | 1.43 | 1.44 | 1.23 | 1.23 | 74.48K |
| Jul 28, 2026 | 1.55 | 1.57 | 1.41 | 1.43 | 85.6K |
| Jul 27, 2026 | 1.69 | 1.69 | 1.44 | 1.53 | 80.52K |
| Jul 24, 2026 | 1.71 | 1.76 | 1.66 | 1.66 | 23.4K |
| Jul 23, 2026 | 1.77 | 1.79 | 1.70 | 1.71 | 29.39K |
| Jul 22, 2026 | 1.75 | 1.84 | 1.75 | 1.81 | 22.23K |
| Jul 21, 2026 | 1.78 | 1.88 | 1.72 | 1.75 | 80.68K |
| Jul 20, 2026 | 1.80 | 1.87 | 1.70 | 1.73 | 96.23K |
| Jul 17, 2026 | 1.83 | 1.84 | 1.80 | 1.80 | 38.27K |
| Jul 16, 2026 | 1.86 | 1.90 | 1.83 | 1.83 | 63.43K |
| Jul 15, 2026 | 1.92 | 1.94 | 1.85 | 1.86 | 44.75K |
| Jul 14, 2026 | 1.95 | 1.96 | 1.91 | 1.92 | 50.74K |
| Jul 13, 2026 | 2.05 | 2.06 | 1.95 | 1.95 | 60.1K |
| Jul 10, 2026 | 2.10 | 2.13 | 2.09 | 2.09 | 20.71K |
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
| Employees | 50 |
| Beta | 1.31 |
| Sales or Revenue | $24.09M |
| 5Y Sales Change% | 66.466% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |